CytoSorbents Corporation (CTSO)

[Makenlight]

Subject: RE: Cytosorbent Patents Vs Appliction Number 12/306670 recorded 3/2010
From: "Phillip Chan" <[e-mail]>
To: XXXXXXX


Thank you XXXXXXXXXXX,

Although I can't comment in detail on this, please understand that the concept of using blood purification to remove "evil humors" is not new. In fact, some have likened it to "21st century bloodletting". However, modern blood purification returns "purified" blood to the body. You will likely find many technologies claiming to remove substances from blood and treating similar diseases. The real test is whether or not they can perform in a real world setting.

In this particular case, the technology appears to be a ligand-based technology - very different from our hemocompatible porous polymer technology. One of the greatest challenges of the former is in the manufacturing and sterilization of such products. That being said, it is interesting, but let me know when you see the technology in the clinic.

Best,
Phillip


--------------------------------------------------------------------------------
From: XXXXXXXXXXXXXXXXXXXXXXX
Sent: Tuesday, April 19, 2011 3:33 PM
To: Phillip Chan
Subject: Cytosorbent Patents Vs Appliction Number 12/306670 recorded 3/2010


Dr Chan,

Let me start this email with congratulatory remarks for the work you have accomplished with the EU approvals; your leadership has been spot on in regards to financing and execution. I have followed CTSO for the past two years and slowly invested moneys into what I see as a world class product and operation. With that being said I have a question relating to our patents. Yesterday in my research I found an approved patent issued to Asahi Kasei Kabushiki Kaisha in Japan. After reviewing the details it seams it closely resembles our products. The three main area of concern are as follows: (excerpt taken from this http://www.freepatentsonline.com/20100069815.pdf)



1. The material of the substrate may be either an inorganic compound or an organic compound as long as it is capable of stably immobilizing at least a predetermined amount of the recognition molecule, although it is preferably a safe material for use as a medical material which can be processed into various forms, which is capable of chemically binding to the recognition molecule either directly or indirectly, and which produces little eluted matter when being contacted with a biological fluid such as blood. Examples thereof can include inorganic materials such as glass, kaolinite, or bentonite, polysaccharide-based compounds of plant origin such as cellulose, natural polymers such as dextran, chitin, chitosan, starch, agarose, protein (collagen etc.), or natural rubber, polypropylene, polystyrene, polyamide, polyethylene, polyurethane, polyvinyl alcohol, ethylene-vinylalcohol copolymer, polymers and copolymers of polymethacrylic ester, polyacrylic ester, polyacrylic acid, polyvinyl alcohol, other vinyl-based compounds, or derivatives thereof, polyamide-based compounds such as Nylon 6 or Nylon 66, polyester-based compounds such as polyethylene terephthalate, synthetic polymers such as polyamino acids, and activated carbon.

2.The term “biorelated substance” among the target substances refers to a biologically produced protein, nucleic acid, lipid, saccharide, low molecular chemical compound, or the like. Further, the term “biorelated substance” used herein can include even an artificial matter such as an endocrine disrupter which seriously affects living bodies. The biorelated substance also includes harmful matters. The term “harmful matter” means, for example, LDL, ß2 microglobulin, drugs, bilirubin, bile acid, amino acids, creatinine, endotoxin, an anti-A antibody, an anti-B antibody, an anti-acetylcholine receptor-antibody, IgG, anti-cardiolipin antibody, anti-DNA antibody, immune complexes, coma-inducing substances, rheumatoid factors, and other plasma components. Abnormal prions are also included therein. In addition, various mediators such as inflammatory cytokines can also serve as harmful matters depending on the pathologic condition. As to inflammatory cytokines, IL-1, IL-6, IL-8, IL-18, TNF-a, GM-CSF, and RANTES/SIS cytokine families are known. Moreover, mediators involved in inflammation include prostaglandin, thromboxane, leukotriene and other products which is produced from arachidonic acid in vivo, platelet activating factors, histamine, bradykinin, and a complement factor C5a.

3. The aforementioned device for biological fluid treatment can be used for the treatment against a disease associated with at least one target substance, selected from a biorelated substance, a bacterium, a cell, a cell aggregation, a virus, or a virus-infected cell. Examples of the disease associated with such target substance(s) can include, but not limited to: (1) acute renal failure, chronic renal failure, and the like; (2) fulminant hepatitis, acute hepatic failure, arteriosclerosia obliterans, myasthenia gravis, Guillain-Barre syndrome, multiple sclerosis, myeloma, drug poisoning, pemphigus, and the like; (3) septic shock, familial hyperlipemia, arteriosclerosia obliterans, focal glomerular sclerosis, dialytic amyloidosis, and the like; and (4) ulcerative colitis, chronic rheumatoid arthritis, multiple sclerosis, dermatosis, and immunological disease.

The target substance in an aqueous solution or blood can be adsorbed or removed by treating this aqueous solution or blood containing the target substance by flowing the aqueous solution or blood through the aforementioned device for biological fluid treatment. Such a treatment method of an aqueous solution and a treatment method of blood are also included in the scope of the present invention.

It seems like the mentioned everything except Cytosorbents: Can you shead some light on the differences and similarities?

I am a long time holder of CTSO stock and have accumulated XXX,XXX shares.

Thank you for all you do,

XXXXXXXXX
XXXXXXXXX
XXXXXXX, XXXXXXXXX